To investigate and assess bone regeneration in sheep in combination with new implant materials classical histological staining methods as well as immunohistochemistry may provide additional information to standard radiographs or computer tomography. Available published data of bone defect regenerations in sheep often present none or sparely labeled histological images. Repeatedly, the exact location of the sample remains unclear, detail enlargements are missing and the labeling of different tissues or cells is absent. The aim of this article is to present an overview of sample preparation, staining methods and their benefits as well as a detailed histological description of bone regeneration in the sheep tibia. General histological staining methods like hematoxylin and eosin, Masson-Goldner trichrome, Movat’s pentachrome and alcian blue were used to define new bone formation within a sheep tibia critical size defect containing a polycaprolactone-co-lactide (PCL) scaffold implanted for 3 months (n = 4). Special attention was drawn to describe the bone healing patterns down to cell level. Additionally one histological quantification method and immunohistochemical staining methods are described.

This diploma thesis deals with use of lactic acid esters for preparation of lactides and PLA. In the theoretical part, it has been processed literature review focus on manufacturing technologies and properties of lactic acid and its esters (especially ethyl ester and lactides). In the experimental part, it has been designed and realized functional laboratory apparatus for preparation of cyclic dimer of lactic acid – lactides. On this apparatus, there were carried out principal laboratory experiments leading to optimization of lactides yields using various catalysts.

Thermoset polymers are widely used polymers in the world, but Increase in global plastic pollution and lack of fossil fuel stimulates intense research towards environmentally sustainable materials. Bio-based unsaturated polyesters (UPs) would be an excellent solution to replace oil-based synthetic polyesters. Most of the unsaturated polyesters have been synthesised by ring opening polymerisation (ROP) of cyclic esters or lactides.  In this study, different resins were developed using different initiators such as isosorbide (IS),1,4 butanediol (BD), and cis-2 butene 1,4 diol (C2BD) with monomers like lactide (L) and alpha angelica lactone (AAL) through the ring opening polymerisation process. The produced resins were further characterised by using Fourier Transform Infrared Spectroscopy (FTIR),Nuclear Magnetic Resonance (NMR), Thermogravimetric Analysis (TGA), Differential Scanning Calorimeter (DSC), and Dynamic Mechanical Analysis (DMA).  Synthesis of resin with lactone monomer was not successful while with lactide monomer it was successful. IS-based resin showed better thermal properties compared to other obtained resins. Tg value of IS containing resin was 63°C, thermal stability up to 235°C and Storage modulus about 3841 MPa. These values are comparable with other bio-based resins produced using the same monomer.

<p>U ovom radu, izvr&scaron;ena je sinteza i karakterizacija bionanokompozitnih materijala na osnovu poli(laktida) i vi&scaron;eslojnih ugljeničnih nanocevi. Ispitivan je uticaj različitih tehnika funkcionalizacije nanocevi, kao i izbor uslova sinteze i odnosa polaznih komponenti sistema, na svojstva dobijenih kompozitnih materijala na osnovu poli(L-laktida). Radi postizanja uniformne raspodele nanopunila u kompozitima, vi&scaron;eslojne ugljenične nanocevi su modifikovane hemijskom i radijacionom funkcionalizacijom. Izvr&scaron;ena je karakterizacija ugljeničnih nanocevi, sa ciljem utvrđivanja uspe&scaron;nosti primenjenih tehnika modifikacije na njihova svojstva i stepen funkcionalizacije. Metodom in situ polimerizacije L-laktida sa povr&scaron;ina modifikovanih nanocevi, pripremljene su serije uzoraka kompozitnih materijala sa različitim sadrţajem funkcionalizovanih nanocevi. Detaljno je ispitan uticaj funkcionalizovanih nanocevi na toplotna, kristalna, morfolo&scaron;ka, mehanička i električna svojstva sintetisanih kompozitnih materijala. Postignuta homogena disperzija nanocevi unutar biorazgradive, biokompatibilne matrice polimera koji se dobija iz obnovljivih sirovina, uticala je na pobolj&scaron;anje svojstava, kao i na uspostavljanje novih funkcionalnosti dobijenih materijala. Značajno pobolj&scaron;anje toplotnih i mehaničkih svojstva sintetisanih materijala, zajedno sa postignutom električnom provodljivo&scaron;ću, omogućava pro&scaron;irenje oblasti primene kompozita na osnovu poli(laktida) i ugljeničnih nanocevi.</p> / <p>In this thesis, bionanocomposites based on poly(lactide) and multi-walled carbon nanotubes were synthesized and characterised. Poly(L-lactide) was used as a matrix for the composite synthesis; the influence of nanofillers content, the methods of their functionalization, as well as the synthesis parameters, on the properties of obtained materials were investigated. In order to achieve a uniform dispersion of nanofillers in composite materials, multi-walled carbon nanotubes were modified using chemical and radiation functionalization. Characterization of carbon nanotubes was performed in order to determine the influence of applied modification techniques on their properties and degree of functionalization. A series of composite materials with different content of modified nanotubes were prepared by in situ polymerization of L-lactide from the surface of functionalized nanotubes. The influence of functionalized nanotubes on the thermal, crystal, morphological, mechanical and electrical properties of synthesized composites was investigated in detail. The homogeneous dispersion of carbon nanotubes within the biodegradable, biocompatible, biobased polymer matrix, has influenced the improvement of the properties, as well as the acquiring of new functionalities of synthesized materials. The significant improvement of thermal and mechanical properties of composites, and the achievement of its electrical conductivity, allow the field of application of composites based on poly(lactide) and carbon nanotubes to be expanded.</p>

The use of synthetic materials for tissue and organ reconstruction, i. e. tissue engineering, has become a promising alternative to current surgical therapies and may overcome the shortcomings of the methods in use today. The challenge is in the design and reproducible fabrication of biocompatible and bioresorbable polymers, with suitable surface chemistry, desirable mechanical properties, and the wanted degradation profile. These material properties can be achieved in various manners, including the synthesis of homo- and copolymers along with linear and star-shaped architectures. In many applications the materials’ three-dimensional structure is almost as important as its composition and porous scaffolds with high porosity and interconnected pores that facilitate the in-growth of cells and transportation of nutrients and metabolic waste is desired. In this work linear and star-shaped polymers have been synthesized by ring-opening polymerization using a stannous-based catalyst and a spirocyclic tin initiator. A series of linear copolymers with various combinations of 1,5-dioxepane-2-one (DXO), Llactide (LLA) and ε-caprolactone (CL) have been polymerized using stannous octoate as catalyst. It is shown that the composition of the polymers can be chosen in such a manner that the materials’ mechanical and thermal properties can be predetermined. A solvent-casting and particulate leaching scaffold preparation technique has been developed and used to create three-dimensional structures with interconnected pores. The achieved physical properties of these materials’ should facilitate their use in both soft and hard tissue regeneration. Well defined star-shaped polyesters have been synthesized using a spirocyclic tin initiator where L-lactide was chosen as a model system for the investigation of the polymerization kinetics. Neither the temperature nor the solvent affects the molecular weight or the molecular weight distribution of the star-shaped polymers, which all show a molecular weight distribution below 1.19 and a molecular weight determined by the initial monomer-to-initiator concentration. / QC 20101217

No description available.

No description available.

Plusieurs agents anticancéreux très puissants sont caractérisés par une solubilité aqueuse limitée et une toxicité systémique importante. Cette dernière serait liée d’une part à la solubilisation des agents anticancéreux à l’aide de surfactifs de bas poids moléculaire, connus pour leur toxicité intrinsèque, et d’autre part, par le manque de spécificité tissulaire des anticancéreux. Les vecteurs colloïdaux à base de polymères permettraient de résoudre certains défis liés à la formulation d’agents anticancéreux hydrophobes. D’abord, les polymères peuvent être sélectionnés afin de répondre à des critères précis de compatibilité, de dégradation et d’affinité pour le médicament à formuler. Ensuite, le fait d’encapsuler l’agent anticancéreux dans un vecteur peut améliorer son efficacité thérapeutique en favorisant son accumulation au niveau du tissu cible, i.e. la tumeur, et ainsi limiter sa distribution au niveau des tissus sains. Des travaux antérieurs menés au sein de notre laboratoire ont mené à la mise au point de micelles à base de poly(N-vinyl-pyrrolidone)-bloc-poly(D,L-lactide) (PVP-b-PDLLA) capables de solubiliser des agents anticancéreux faiblement hydrosolubles dont le PTX. Ce dernier est commercialisé sous le nom de Taxol® et formulé à l’aide du Crémophor EL (CrEL), un surfactif de bas poids moléculaire pouvant provoquer, entre autres, des réactions d’hypersensibilité sévères. Bien que les micelles de PVP-b-PDLLA chargées de PTX aient démontré une meilleure tolérance comparée au Taxol®, leur potentiel de ciblage tumoral et leur efficacité thérapeutique étaient similaires à la forme commerciale à doses égales. Ceci était possiblement dû au fait que les micelles étaient rapidement déstabilisées et ne pouvaient retenir leur cargo suite à leur administration intraveineuse. Nous avons donc décidé de poursuivre les travaux avec un autre type de vecteur, soit des nanoparticules, qui possèdent une stabilité intrinsèque supérieure aux micelles. L’objectif principal de cette thèse de doctorat était donc de mettre au point des nanoparticules polymères pour l’administration parentérale d’agents anticancéreux faiblement solubles dans l’eau. Les nanoparticules devaient permettre d’encapsuler des agents anticancéreux hydrophobes et de les libérer de manière contrôlée sur plusieurs jours. De plus, elles devaient démontrer un temps de circulation plasmatique prolongée afin de favoriser l’accumulation passive du médicament encapsulé au niveau de la tumeur. La première partie du travail visait à employer pour la première fois le copolymère amphiphile PVP-b-PDLLA comme émulsifiant dans la préparation de nanoparticules polymères. Ainsi, une méthode de fabrication des nanoparticules par émulsion huile-dans-eau a été appliquée afin de produire des nanoparticules à base de PDLLA de taille inférieure à 250 nm. Grâce aux propriétés lyoprotectrices de la couronne de PVP présente à la surface des nanoparticules, celles-ci pouvaient retrouver leur distribution de taille initiale après lyophilisation et redispersion en milieu aqueux. Deux anticancéreux hydrophobes, soit le PTX et l’étoposide (ETO), ont été encapsulés dans les nanoparticules et libérés de ces dernières de façon contrôlée sur plusieurs jours in vitro. Une procédure de « salting-out » a été appliquée afin d’améliorer le taux d’incorporation de l’ETO initialement faible étant donnée sa solubilité aqueuse légèrement supérieure à celle du PTX. Le second volet des travaux visait à comparer le PVP comme polymère de surface des nanoparticules au PEG, le polymère le plus fréquemment employé à cette fin en vectorisation. Par le biais d’études d’adsorption de protéines, de capture par les macrophages et de biodistribution chez le rat, nous avons établi une corrélation in vitro/in vivo démontrant que le PVP n’était pas un agent de surface aussi efficace que le PEG. Ainsi, malgré la présence du PVP à la surface des nanoparticules de PDLLA, ces dernières étaient rapidement éliminées de la circulation sanguine suite à leur capture par le système des phagocytes mononucléés. Par conséquent, dans le troisième volet de cette thèse, le PEG a été retenu comme agent de surface, tandis que différents polymères biodégradables de la famille des polyesters, certains synthétiques (PDLLA et copolymères d’acide lactique/acide glycolique), d’autres de source naturelle (poly(hydroxyalkanoates)(PHAs)), ont été investiguées comme matériaux formant le cœur des nanoparticules. Il en est ressorti que les propriétés physicochimiques des polyesters avaient un impact majeur sur l’efficacité d’encapsulation du PTX et son profil de libération des nanoparticules in vitro. Contrairement aux PHAs, les polymères synthétiques ont démontré des taux d’incorporation élevés ainsi qu’une libération contrôlée de leur cargo. Des études de pharmacocinétique et de biodistribution ont démontré que les nanoparticules de PDLLA dotées d’une couronne de PEG conféraient un temps de circulation plasmatique prolongé au PTX et favorisaient son accumulation tumorale. Les nanoparticules polymères représentent donc une alternative intéressante au Taxol®. / Many highly potent anticancer drugs are characterized by poor aqueous solubility and can impart significant systemic toxicity. This toxicity can be attributed in part to the solubilisation of these anticancer agents with low molecular weight surfactants that are known to cause serious biological side effects on their own. Moreover, following their intravenous (IV) injection, the anticancer agents distribute throughout the body, causing deleterious effects in healthy organs and tissues. Colloidal polymeric drug carriers have been investigated as a means to circumvent these drawbacks. First, polymeric materials can be tailored to meet specific requirements in terms of biocompatibility, biodegradability and affinity for the cargo molecule. Second, associating a drug to a carrier system can drastically alter its distribution throughout the body, enhancing its deposition at the target site, e.g. the tumour, while sparing healthy tissues, thus minimizing systemic toxicity. Previous work in our group has led to the design of block copolymer micelles based on poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) that were shown to solubilise hydrophobic anticancer agents such as paclitaxel (PTX). PTX is commercially available as Taxol®, a Cremophor EL (CrEL)-based formulation. CrEL is a low molecular weight surfactant that has been linked to severe side effects including life-threatening hypersensitivity reactions. Although PTX-loaded PVP-b-PDLLA micelles have demonstrated much improved tolerability compared to Taxol®, they did not increase PTX tumoral concentrations and exhibited anticancer efficacy similar to Taxol® at equivalent dosage. This was attributed to rapid destabilisation of the micelles and release of their cargo following IV administration. We chose to pursue our work with a colloidal drug carrier that exhibits greater stability compared to block copolymer micelles, i.e. polymeric nanoparticles. The main objective of this project was to develop polymeric nanoparticles for the parenteral delivery of hydrophobic anticancer drugs. The nanoparticles had to meet certain requirements such as be able to encapsulate hydrophobic anticancer drugs and release them in a controlled fashion over several days. Furthermore, the nanoparticles should confer prolonged plasma residence times to the encapsulated drug and favour its passive accumulation at its intended site of action, i.e. the tumour. The first part of this work focussed on applying PVP-b-PDLLA for the first time as polymeric emulsifier for the preparation of PDLLA nanoparticles with appropriate mean diameters (250 nm) using an oil-in-water emulsion method. Two hydrophobic anticancer drugs, PTX and etoposide (ETO), were successfully incorporated into the nanoparticles. A salting-out method was applied to enhance the loading efficiency of ETO, which was initially low given its slightly higher aqueous solubility compared to PTX. Both drugs were released in a controlled fashion from the PDLLA nanoparticles in vitro. Because of the lyoprotective effect of PVP, the polymer corona allowed for the particles to be easily redispersed in aqueous media following lyophilisation. The second part of the thesis aimed at evaluating whether the PVP coating could confer “stealth” properties to the PDLLA nanoparticles. Our study provided direct comparison between PVP and PEG, the most widely employed surface agent in drug delivery. In vitro protein adsorption and phagocytosis studies corroborated the in vivo findings, which showed that PVP-coated nanoparticles were rapidly cleared from circulation following their uptake by the mononuclear phagocyte system. Hence, our results indicated that PVP as coating materiel is not as efficient as PEG in conferring “stealth” properties to polymeric nanoparticles. Consequently, in the last section of this thesis, PEG was selected as coating agent while various biodegradable polymers were investigated as core-forming materials. Both synthetic (PDLLA and lactide/glycolide copolymers) and natural (polyhydroxyalkanoates (PHAs)) polyesters were tested. Our results demonstrated that the physicochemical properties of the polyesters significantly influenced the loading efficiency and release kinetics of PTX. While nanoparticles based on synthetic polyesters exhibited high encapsulation levels and controlled PTX release in vitro, PHA-based nanoparticles exhibited immediate unloading of their cargo. Pharmacokinetic and biodistribution studies in rodents revealed that encapsulating PTX in PEG-coated PDLLA-based nanoparticles led to enhanced plasma residence time and tumour deposition of the drug compared to Taxol®. Polymeric nanoparticles thus represent an appealing alternative to Taxol®.

<p>Degradable polymers have gained an increased attention in the field of biomedical applications over the past decades, for example in tissue engineering. One way of improving the biocompatibility of these polymers is by chemical surface modification, however the risk of degradation during the modification procedure is a limiting factor. In some biomedical applications, for example in nerve guides, a patterned surface is desired to improve the cell attachment and proliferation.</p><p>In this thesis a new non-destructive, single-step, and solvent free method for surface modification of degradable polymers is described. Poly(L-lactide) (PLLA) substrates have been functionalized with one of the following vinyl monomers; N-vinylpyrrolidone (VP), acrylamide (AAm), or maleic anhydride (MAH) grafts. The substrates were subjected to a vapor phase atmosphere constituted of a mixture of a vinyl monomer and a photoinitiator (benzophenone) in a closed chamber at very low pressure and under UV irradiation. Poly(ε-caprolactone) (PCL), poly(lactide-co-glycolide) (PLGA), and poly(trimethylene carbonate) (PTMC) have been surface modified with VP using the same procedure to show the versatility of the method. The wettability of all of the four substrates increased after grafting. The surface compositions were confirmed by ATR-FTIR and XPS. The VP grafted PLLA, PTMC and PLGA substrates have been shown to be good substrates for the normal human cells i.e. keratinocytes and fibroblasts, to adhere and proliferate on. The topography of substrates with well defined nano patterns was preserved during grafting, since the grafted layer is very thin. We have also shown that the method is useful for a simultaneous chemical and topographical modification of substrates by masked vapor phase grafting. The surface topography was determined with SEM and AFM.</p> / <p>Intresset för användningen av nedbrytbara polymerer till biomedicinska applikationer som till exempel vävnads rekonstruktion har ökat avsevärt de senaste decennierna. Ett sätt att öka biokompatibiliteten hos dessa polymerer är genom kemisk ytmodifiering, men risken för nedbrytning under själva modifieringen är en begränsande faktor. I vissa biomedicinska applikationer, till exempel nervguider, är det önskvärt att ha en väldefinierad ytstruktur för att öka vidhäftningen och tillväxten av celler.</p><p>I den här avhandlingen presenteras en ny ickeförstörande, lösningsmedelsfri enstegsprocess för ytmodifiering av nedbrytbara polymerer. Substrat av poly(L-laktid) (PLLA) har ytfunktionaliserats med var och en av följande vinylmonomerer, N-vinylpyrrolidon (VP), akrylamid (AAm) eller maleinsyraanhydrid (MAH). Substraten har exponerats för en gasfasatmosfär av en blandning av en vinylmonomer och en fotoinitiator (bensofenon) i en tillsluten reaktor vid mycket lågt tryck och under UV-strålning. Metodens mångsidighet har även påvisats genom att ytmodifiera substrat av poly(ε-kaprolakton) (PCL), poly(laktid-co-glykolid) (PLGA) och poly(trimetylen karbonat) (PTMC) med VP. Vätbarheten ökade för alla fyra materialen efter ympning med en vinylmonomer. Ytsammansättningen fastställdes med ATR-FTIR och XPS. De VP ympade filmerna av PLLA, PLGA och PTMC visade sig vara bra substrat för mänskliga celler, i detta fall keratinocyter och fibroblaster, att vidhäfta och växa på. Yttopografin hos filmer med väldefinierade nanomönstrade ytor kunde bevaras efter ympning, tack vare att det ympade lagret är så tunt. Gasfas metoden har också visat sig användbar för att simultant ytmodifiera både kemiskt och topografiskt genom maskad gasfasympning. Yttopografin bestämdes med SEM och AFM.</p>

Plusieurs agents anticancéreux très puissants sont caractérisés par une solubilité aqueuse limitée et une toxicité systémique importante. Cette dernière serait liée d’une part à la solubilisation des agents anticancéreux à l’aide de surfactifs de bas poids moléculaire, connus pour leur toxicité intrinsèque, et d’autre part, par le manque de spécificité tissulaire des anticancéreux. Les vecteurs colloïdaux à base de polymères permettraient de résoudre certains défis liés à la formulation d’agents anticancéreux hydrophobes. D’abord, les polymères peuvent être sélectionnés afin de répondre à des critères précis de compatibilité, de dégradation et d’affinité pour le médicament à formuler. Ensuite, le fait d’encapsuler l’agent anticancéreux dans un vecteur peut améliorer son efficacité thérapeutique en favorisant son accumulation au niveau du tissu cible, i.e. la tumeur, et ainsi limiter sa distribution au niveau des tissus sains. Des travaux antérieurs menés au sein de notre laboratoire ont mené à la mise au point de micelles à base de poly(N-vinyl-pyrrolidone)-bloc-poly(D,L-lactide) (PVP-b-PDLLA) capables de solubiliser des agents anticancéreux faiblement hydrosolubles dont le PTX. Ce dernier est commercialisé sous le nom de Taxol® et formulé à l’aide du Crémophor EL (CrEL), un surfactif de bas poids moléculaire pouvant provoquer, entre autres, des réactions d’hypersensibilité sévères. Bien que les micelles de PVP-b-PDLLA chargées de PTX aient démontré une meilleure tolérance comparée au Taxol®, leur potentiel de ciblage tumoral et leur efficacité thérapeutique étaient similaires à la forme commerciale à doses égales. Ceci était possiblement dû au fait que les micelles étaient rapidement déstabilisées et ne pouvaient retenir leur cargo suite à leur administration intraveineuse. Nous avons donc décidé de poursuivre les travaux avec un autre type de vecteur, soit des nanoparticules, qui possèdent une stabilité intrinsèque supérieure aux micelles. L’objectif principal de cette thèse de doctorat était donc de mettre au point des nanoparticules polymères pour l’administration parentérale d’agents anticancéreux faiblement solubles dans l’eau. Les nanoparticules devaient permettre d’encapsuler des agents anticancéreux hydrophobes et de les libérer de manière contrôlée sur plusieurs jours. De plus, elles devaient démontrer un temps de circulation plasmatique prolongée afin de favoriser l’accumulation passive du médicament encapsulé au niveau de la tumeur. La première partie du travail visait à employer pour la première fois le copolymère amphiphile PVP-b-PDLLA comme émulsifiant dans la préparation de nanoparticules polymères. Ainsi, une méthode de fabrication des nanoparticules par émulsion huile-dans-eau a été appliquée afin de produire des nanoparticules à base de PDLLA de taille inférieure à 250 nm. Grâce aux propriétés lyoprotectrices de la couronne de PVP présente à la surface des nanoparticules, celles-ci pouvaient retrouver leur distribution de taille initiale après lyophilisation et redispersion en milieu aqueux. Deux anticancéreux hydrophobes, soit le PTX et l’étoposide (ETO), ont été encapsulés dans les nanoparticules et libérés de ces dernières de façon contrôlée sur plusieurs jours in vitro. Une procédure de « salting-out » a été appliquée afin d’améliorer le taux d’incorporation de l’ETO initialement faible étant donnée sa solubilité aqueuse légèrement supérieure à celle du PTX. Le second volet des travaux visait à comparer le PVP comme polymère de surface des nanoparticules au PEG, le polymère le plus fréquemment employé à cette fin en vectorisation. Par le biais d’études d’adsorption de protéines, de capture par les macrophages et de biodistribution chez le rat, nous avons établi une corrélation in vitro/in vivo démontrant que le PVP n’était pas un agent de surface aussi efficace que le PEG. Ainsi, malgré la présence du PVP à la surface des nanoparticules de PDLLA, ces dernières étaient rapidement éliminées de la circulation sanguine suite à leur capture par le système des phagocytes mononucléés. Par conséquent, dans le troisième volet de cette thèse, le PEG a été retenu comme agent de surface, tandis que différents polymères biodégradables de la famille des polyesters, certains synthétiques (PDLLA et copolymères d’acide lactique/acide glycolique), d’autres de source naturelle (poly(hydroxyalkanoates)(PHAs)), ont été investiguées comme matériaux formant le cœur des nanoparticules. Il en est ressorti que les propriétés physicochimiques des polyesters avaient un impact majeur sur l’efficacité d’encapsulation du PTX et son profil de libération des nanoparticules in vitro. Contrairement aux PHAs, les polymères synthétiques ont démontré des taux d’incorporation élevés ainsi qu’une libération contrôlée de leur cargo. Des études de pharmacocinétique et de biodistribution ont démontré que les nanoparticules de PDLLA dotées d’une couronne de PEG conféraient un temps de circulation plasmatique prolongé au PTX et favorisaient son accumulation tumorale. Les nanoparticules polymères représentent donc une alternative intéressante au Taxol®. / Many highly potent anticancer drugs are characterized by poor aqueous solubility and can impart significant systemic toxicity. This toxicity can be attributed in part to the solubilisation of these anticancer agents with low molecular weight surfactants that are known to cause serious biological side effects on their own. Moreover, following their intravenous (IV) injection, the anticancer agents distribute throughout the body, causing deleterious effects in healthy organs and tissues. Colloidal polymeric drug carriers have been investigated as a means to circumvent these drawbacks. First, polymeric materials can be tailored to meet specific requirements in terms of biocompatibility, biodegradability and affinity for the cargo molecule. Second, associating a drug to a carrier system can drastically alter its distribution throughout the body, enhancing its deposition at the target site, e.g. the tumour, while sparing healthy tissues, thus minimizing systemic toxicity. Previous work in our group has led to the design of block copolymer micelles based on poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) that were shown to solubilise hydrophobic anticancer agents such as paclitaxel (PTX). PTX is commercially available as Taxol®, a Cremophor EL (CrEL)-based formulation. CrEL is a low molecular weight surfactant that has been linked to severe side effects including life-threatening hypersensitivity reactions. Although PTX-loaded PVP-b-PDLLA micelles have demonstrated much improved tolerability compared to Taxol®, they did not increase PTX tumoral concentrations and exhibited anticancer efficacy similar to Taxol® at equivalent dosage. This was attributed to rapid destabilisation of the micelles and release of their cargo following IV administration. We chose to pursue our work with a colloidal drug carrier that exhibits greater stability compared to block copolymer micelles, i.e. polymeric nanoparticles. The main objective of this project was to develop polymeric nanoparticles for the parenteral delivery of hydrophobic anticancer drugs. The nanoparticles had to meet certain requirements such as be able to encapsulate hydrophobic anticancer drugs and release them in a controlled fashion over several days. Furthermore, the nanoparticles should confer prolonged plasma residence times to the encapsulated drug and favour its passive accumulation at its intended site of action, i.e. the tumour. The first part of this work focussed on applying PVP-b-PDLLA for the first time as polymeric emulsifier for the preparation of PDLLA nanoparticles with appropriate mean diameters (250 nm) using an oil-in-water emulsion method. Two hydrophobic anticancer drugs, PTX and etoposide (ETO), were successfully incorporated into the nanoparticles. A salting-out method was applied to enhance the loading efficiency of ETO, which was initially low given its slightly higher aqueous solubility compared to PTX. Both drugs were released in a controlled fashion from the PDLLA nanoparticles in vitro. Because of the lyoprotective effect of PVP, the polymer corona allowed for the particles to be easily redispersed in aqueous media following lyophilisation. The second part of the thesis aimed at evaluating whether the PVP coating could confer “stealth” properties to the PDLLA nanoparticles. Our study provided direct comparison between PVP and PEG, the most widely employed surface agent in drug delivery. In vitro protein adsorption and phagocytosis studies corroborated the in vivo findings, which showed that PVP-coated nanoparticles were rapidly cleared from circulation following their uptake by the mononuclear phagocyte system. Hence, our results indicated that PVP as coating materiel is not as efficient as PEG in conferring “stealth” properties to polymeric nanoparticles. Consequently, in the last section of this thesis, PEG was selected as coating agent while various biodegradable polymers were investigated as core-forming materials. Both synthetic (PDLLA and lactide/glycolide copolymers) and natural (polyhydroxyalkanoates (PHAs)) polyesters were tested. Our results demonstrated that the physicochemical properties of the polyesters significantly influenced the loading efficiency and release kinetics of PTX. While nanoparticles based on synthetic polyesters exhibited high encapsulation levels and controlled PTX release in vitro, PHA-based nanoparticles exhibited immediate unloading of their cargo. Pharmacokinetic and biodistribution studies in rodents revealed that encapsulating PTX in PEG-coated PDLLA-based nanoparticles led to enhanced plasma residence time and tumour deposition of the drug compared to Taxol®. Polymeric nanoparticles thus represent an appealing alternative to Taxol®.